Agenus Inc. — Q3 2011 Form 10-Q
Business context and period. Biotechnology company developing cancer and infectious-disease therapies, principally through its Prophage heat-shock-protein vaccine platform and QS-21 adjuvant platform. This unaudited report covers the quarter and nine months ended September 30, 2011. Share and per-share figures are retroactively adjusted for the one-for-six reverse split effective October 3, 2011.
Key financial results
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Revenue | $654,000 | $624,000 | $2.112 million | $2.366 million |
| Operating loss | $(4.441) million | $(4.887) million | $(14.165) million | $(16.797) million |
| Net loss | $(5.534) million | $(5.707) million | $(17.256) million | $(19.490) million |
| Net loss attributable to common stockholders | $(5.732) million | $(5.905) million | $(17.849) million | $(20.083) million |
| Loss per common share, basic and diluted | $(0.28) | $(0.36) | $(0.92) | $(1.26) |
- Quarterly R&D expense was $2.528 million versus $2.822 million; nine-month R&D was $8.167 million versus $10.082 million. G&A was $2.567 million for Q3 and $8.110 million for nine months.
- No product revenue or cost of goods sold was recorded in 2011. Revenue was primarily research-and-development revenue, license fees and royalties; deferred-revenue amortization contributed $385,000 in each quarter and $1.2 million in each nine-month period.
- Nine-month revenue declined mainly because of fewer QS-21 shipments. Operating expenses fell with cost containment and lower program spending. The 2010 comparison included non-operating gains, notably a $1.1 million gain on extinguishment of debt; there was no similar activity in 2011.
- Net cash used in operating activities was $12.069 million for the first nine months, compared with $13.313 million in 2010. Net cash from financing was $7.049 million, including $7.559 million net equity proceeds. Cash and cash equivalents fell $5.050 million to $14.732 million from December 31, 2010.
- At September 30, current assets were $15.985 million and current liabilities $5.865 million. Total assets were $24.369 million; stockholders’ deficit was $16.071 million. Debt principal was approximately $36.5 million, including $36.1 million of 8% senior secured convertible notes due August 2014 and $100,000 of 2005 notes. The 2006 notes are secured by subsidiary equity associated with QS-21 and HerpV.
Outlook, developments and risks
- Management estimated 2011 net cash burn of $16–18 million and expected existing working capital and anticipated agreement proceeds to meet liquidity needs into 2012. The company intended to seek additional capital before funds were depleted, through licensing, renegotiations, asset sales, debt or equity financing. It warned that unavailable or unacceptable financing could force program reductions, asset transactions or threaten continued operations.
- The company expected significant losses to continue. It could not reliably estimate the cost or timing of completing development programs or when material operating cash inflows might begin. Potential QS-21 royalties were anticipated around 2013–2014, contingent on licensees’ clinical, regulatory and commercialization success.
- Oncophage was approved in Russia for intermediate-risk kidney cancer, but sales were minimal and the company was seeking a commercial partner. Its European application had received a negative opinion and was withdrawn. Phase 2 studies of Prophage G-100 and G-200 in glioma were ongoing; management planned a Phase 2 HerpV trial in 2012, subject to funding or partnership, while describing the program as generally on hold under cost containment.
- In February 2011, amendments extended the 2006 notes’ maturity to August 2014, removed the right to convert them into Agenus common stock, and changed accounting for the conversion feature. Holders retain specified rights relating to equity in the subsidiary securing the notes. The company issued approximately 2.3 million shares in an August underwritten offering, netting about $6.3 million.
- After Nasdaq bid-price noncompliance, the company effected a one-for-six reverse split on October 3, 2011. Nasdaq notified it on October 17 that it had regained bid-price compliance and met continued-listing requirements.
- Principal risks include limited liquidity and substantial debt; uncertain access to capital; clinical-trial, regulatory and manufacturing failure or delay; reliance on licensees and collaborators; uncertain QS-21 royalties and Oncophage commercialization; competition and intellectual-property exposure; and possible dilution or renewed Nasdaq noncompliance.
- A class action relating to the company’s IPO had a court-approved global settlement funded by insurers, with appeals by objectors still pending. The company recorded no accrual and said it could not estimate potential liability if the settlement did not become effective.
Important facts for investors to verify
- Cash runway and actual subsequent financing relative to the stated expectation of liquidity into 2012 and $16–18 million 2011 net cash burn.
- Debt terms, interest paid in additional notes, maturity obligations, and any impact of noteholder rights over the QS-21/HerpV subsidiary.
- Clinical-trial progress and regulatory prospects for Prophage and HerpV, plus partner-led QS-21 programs and the basis for expected royalty timing.
- Commercial partner, reimbursement, collections and sales progress for Oncophage in Russia.
- Potential dilution, including equity financing and outstanding warrants, options and convertible preferred stock; the filing reports 21,455,205 common shares outstanding as of November 2, 2011.
- Developments in the IPO settlement appeals and continued compliance with Nasdaq listing requirements.